Sorafenib pharmacokinetics in non small cell lung cancer patients: an in;vivo study using positron emission tomography
Completed
- Conditions
- lung cancer10038666
- Registration Number
- NL-OMON37648
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
• Patients age of 18-70 years;
• Patients with advanced non small cell lung cancer harboring a K-Ras mutation;
• Life expectancy of at least 12 weeks;
• Malignant lesion of at least 1.5 cm diameter within the chest as;
measured by CT;
• Performance status Karnofsky index >60%;
• Laboratory requirements;
• Written informed consent
Exclusion Criteria
• Claustrophobia;
• Pregnant or lactating patients;
• Patients having metal implants (e.g. pacemakers);
• Concurrent or previous treatment with experimental drugs
Anemia
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>[11C]sorafenib pharmacokinetics</p><br>
- Secondary Outcome Measures
Name Time Method <p>1. Comparison of venous versus arterial sampling<br /><br>2. Reproducibility of [11C]sorafenib PET-CT measurements<br /><br>3. Relationship between K-Ras mutations and [11C]sorafenib pharmacokinetics in<br /><br>tumor tissue<br /><br>4. Study the relation between tumor blood flow and [11C]sorafenib uptake in<br /><br>tumors</p><br>